Clinical Trial Update: Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) [Phase 1]

View source ↗

Summary

Phase 1 study of oral ruxolitinib in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Myelofibrosis | Phase 1 | Status: COMPLETED | Results posted: 2022-03-09